Focusing on the theme of Translating Science into Survival, the Ninth International Cancer Immunotherapy Conference (CICON25) will spotlight new research and critical discussions that push the frontiers of cancer treatments.

CICON25 will present plenary lectures, proffered talks, roundtable discussions, poster sessions, as well as industry exhibits. Proffered talks will be selected from submitted abstracts, showcasing the latest advancements in cancer immunotherapy. Poster sessions will offer a platform for in-depth discussions on specific studies, encouraging collaborative exploration and innovation.

Ahead of the main conference, a pre-conference program will take place on September 9. A dedicated workshop on tertiary lymphoid structures will explore their induction, regulation, spatial organization, function, and predictive potential in the context of cancer immunotherapy. Additionally, the L´Institut Servier will host a symposium on neuro-immuno-oncology exploring the complex interactions between the nervous system, the immune system, and cancer, with a particular focus on brain tumors.

ESMO 2025 will be a place where groundbreaking discoveries, cutting-edge treatments and a collaborative approach converge to shape the future of cancer care.

You will be able to learn from internationally renowned experts, engage in thought-provoking discussions and connect with fellow oncology professionals that are driving advancements in diagnosis, treatment and survivorship.

Save the date for ESMO 2025, taking place in Berlin, Germany 17-21 October 2025.

Wednesday, Nov. 5–Sunday, Nov. 9, 2025, at the Gaylord National Resort and Convention Center National Harbor, Md. Details TBD.

This international event provides valuable knowledge: from basic science to translational research and clinical development, cutting-edge science, and excellent networking opportunities. Program TBD.

This meeting will bring together a diverse group of basic, translational and clinical researchers including those from academia, industry and government to cooperatively discuss the mechanistic basis of failed immunotherapy, and novel approaches to activating the immune system, in order to provide insight for future clinical applications of novel approaches and optimal combination therapies.